Literature DB >> 25367832

The accuracy of home monitoring to detect disease activity during maintenance therapy for neovascular ARMD.

Martin McKibbin1, Lucy Baker, Paul Baxter, Carolyn Czoski-Muray, Roopa Setty.   

Abstract

PURPOSE: To report the reproducibility, sensitivity, specificity, and predictive value of home monitoring for disease activity in neovascular age-related macular degeneration (ARMD).
METHODS: Participants were trained to complete three separate home monitoring tasks, designed to identify subtle changes in visual function that may indicate increasing neovascular ARMD disease activity. These included measurement of near acuity and assessments of environmental distortion and overall visual function. The need for repeat intra-vitreal injection, as predicted by home monitoring, was compared to standard clinical assessment involving ETDRS distance acuity, slit lamp examination, and spectral domain ocular coherence tomography.
RESULTS: Although all participants were able to complete the home monitoring tasks, the reproducibility of each of the three tasks was modest. Cohen's kappa was 0.118 (p = 0.54) for the comparison of the outcome of the home monitoring exercise with the gold standard of hospital assessment to determine disease activity. The sensitivity of the home monitoring exercise was 33.3 % (95 % CI 15.2-51.4) and the specificity was 77.8 % (95 % CI 61.8-93.8).
CONCLUSIONS: This study suggests that current tests of visual function, which are readily completed at home, cannot replace traditional clinic-based assessments for neovascular ARMD disease activity. Instead, such tests are likely to remain complementary to standard assessment in clinic.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25367832     DOI: 10.1007/s00417-014-2839-4

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  19 in total

1.  Shape perception is altered by normal aging.

Authors:  Anne E Weymouth; Allison M McKendrick
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-05-31       Impact factor: 4.799

2.  Preferential hyperacuity perimeter as a functional tool for monitoring exudative age-related macular degeneration in patients treated by intravitreal ranibizumab.

Authors:  Giuseppe Querques; Lea Querques; Omer Rafaeli; Florence Canoui-Poitrine; Francesco Bandello; Eric H Souied
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-09-01       Impact factor: 4.799

Review 3.  Diagnostic accuracy of the Amsler grid and the preferential hyperacuity perimetry in the screening of patients with age-related macular degeneration: systematic review and meta-analysis.

Authors:  L Faes; N S Bodmer; L M Bachmann; M A Thiel; M K Schmid
Journal:  Eye (Lond)       Date:  2014-05-02       Impact factor: 3.775

4.  The intraclass correlation coefficient as a measure of reliability.

Authors:  J J Bartko
Journal:  Psychol Rep       Date:  1966-08

5.  Environmental Amsler test as a monitoring tool for retreatment with ranibizumab for neovascular age-related macular degeneration.

Authors:  R Mathew; S Sivaprasad
Journal:  Eye (Lond)       Date:  2011-12-16       Impact factor: 3.775

6.  Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials.

Authors:  P Mitchell; J-F Korobelnik; P Lanzetta; F G Holz; C Prünte; U Schmidt-Erfurth; Y Tano; S Wolf
Journal:  Br J Ophthalmol       Date:  2009-05-13       Impact factor: 4.638

Review 7.  Macular function surveillance revisited.

Authors:  Richard Trevino; Michael G Kynn
Journal:  Optometry       Date:  2008-07

8.  Feasibility of a novel remote daily monitoring system for age-related macular degeneration using mobile handheld devices: results of a pilot study.

Authors:  Peter K Kaiser; Yi-Zhong Wang; Yu-Guang He; Annemarie Weisberger; Stephane Wolf; Craig H Smith
Journal:  Retina       Date:  2013-10       Impact factor: 4.256

9.  A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study.

Authors:  Geeta A Lalwani; Philip J Rosenfeld; Anne E Fung; Sander R Dubovy; Stephen Michels; William Feuer; Janet L Davis; Harry W Flynn; Maria Esquiabro
Journal:  Am J Ophthalmol       Date:  2009-04-18       Impact factor: 5.258

10.  Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial.

Authors:  Usha Chakravarthy; Simon P Harding; Chris A Rogers; Susan M Downes; Andrew J Lotery; Sarah Wordsworth; Barnaby C Reeves
Journal:  Ophthalmology       Date:  2012-05-11       Impact factor: 12.079

View more
  2 in total

1.  Subjective evaluation of visual acuity is not reliable to detect disease activity in different exudative maculopathies.

Authors:  Marie-Christine Bruender; Nicola Benjamin; Hansjuergen Thomas Agostini; Andreas Stahl; Christoph Ehlken
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-06-01       Impact factor: 3.117

2.  Action on neovascular age-related macular degeneration (nAMD): recommendations for management and service provision in the UK hospital eye service.

Authors:  Richard P Gale; Sajjad Mahmood; Helen Devonport; Praveen J Patel; Adam H Ross; Gavin Walters; Louise Downey; Samer El-Sherbiny; Mary Freeman; Simon Berry; Nitin Jain
Journal:  Eye (Lond)       Date:  2019-03       Impact factor: 3.775

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.